Gilead Announces Share Repurchase Program

FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 22, 2007--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company's Board of Directors has authorized the repurchase of up to $3.0 billion of the company's common stock through December 2010.

Purchases may be made in the open market or in privately negotiated transactions from time to time, as determined by Gilead's management and in accordance with the requirements of the Securities and Exchange Commission. As of September 30, 2007, Gilead had approximately 928,864,666 shares of common stock outstanding.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in the Gilead Annual Report on Form 10-K for the year ended December 31, 2006 and its Quarterly Reports on Form 10-Q for the first and second quarters of 2007 as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update any such forward-looking statements.

For more information on Gilead Sciences, please visit the company's website at www.gilead.com or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Amy Flood, 650-522-5643 (Media)
SOURCE: Gilead Sciences, Inc.